DaVita (NYSE: DVA) was downgraded by investment analysts at Feltl & Co. from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday. They currently have a $100.00 target price on the stock, down from their previous target price of $103.00.
Shares of DaVita opened at 85.28 on Thursday. DaVita has a one year low of $59.14 and a one year high of $90.42. The company has a market cap of $7.991 billion and a P/E ratio of 15.62.
The company last announced its quarterly results on Thursday, February 16th. It reported $1.58 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $1.49 EPS by $0.09. The company’s quarterly revenue was up 13.1% on a year-over-year basis. On average, analysts predict that DaVita will post $1.61 earnings per share next quarter.
DVA has been the subject of a number of other recent research reports. Analysts at Robert W. Baird downgraded shares of DaVita from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday. They now have a $90.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of DaVita in a research note to investors on Wednesday. They now have a $94.00 price target on the stock. Finally, analysts at Zacks downgraded shares of DaVita from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, March 7th. They now have a $90.00 price target on the stock.
DaVita Inc. is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, which is an end stage renal disease (ESRD).